Pattern and chemosensitivity of ovarian cancer in patients with BRCA1/2 mutations

Journal of Obstetrics and Gynaecology

Volumn 31, Issue 2, 2011, Pages 178-179

  Ragupathy, K ^a   Ferguson, M ^a  

^a NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

chemosensitivity; Hereditary ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DOXORUBICIN; IFOSFAMIDE; PLATINUM DERIVATIVE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CARCINOSARCOMA; CHEMOSENSITIVITY; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DOXORUBICIN; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; IFOSFAMIDE; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; SURVIVAL RATE;

EID: 79551533342     PISSN: 01443615     EISSN: 13646893     Source Type: Journal    
DOI: 10.3109/01443615.2010.539719     Document Type: Article

References (16)

1. Adami HO, Hsieh CC, Lambe M. 1994. Parity, age of first childbirth, and risk of ovarian cancer. Lancet 344:1250-1254.
2. Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL et al. 2000. Clinicopathologic features of BRCA-Linked and sporadic ovarian cancer. Journal of the American Medical Association 283:2260-2265.
3. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY et al. 2003. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97:2187-2195.
4. David YB, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD, Beller U et al. 2002. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. Journal of Clinical Oncology 20:463-466.
5. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P et al. 1998. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. American Journal of Human Genetics 62:676-689.
6. Gien LT, Mackay HJ. 2010. The emerging role of PARP inhibitors in the treatment of epithelial ovarian cancer. Journal of Oncology 2010:151750.
7. Martinek I, Haldar K, Gaitskell K, Bryant A, Nicum S, Kehoe S et al. 2010. DNA-repair pathway inhibitors for the treatment of ovarian cancer. Cochrane Database of Systematic Reviews 6:CD007929.
8. Pharoah PD, Easton DF, Stockton DL, Gayther S, Ponder BA. 1999. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. Cancer Research 59:868-871.
9. Pharoah PD, Ponder BA. 2002. The genetics of ovarian cancer. Best practice and Research Clinical Obstetrics and Gynaecology 16:449-468.
10. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E et al. 2001. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. American Journal of Human Genetics 68:700-710.
11. Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, Livolsi VA et al. 1996. Clinical and pathologic features of ovarian cancer in women with germ-line mutations of BRCA1. New England Journal of Medicine 335:1413-1416.
12. Shaw PA, McLaughlin JR, Zweemer RP, Narod SA, Risch H, Verheijen RH et al. 2002. Histopathologic features of genetically determined ovarian cancer. International Journal of Gynecological Pathology 21:407-411.
13. Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S et al. 2008. 'BRCAness' syndrome in ovarian cancer: a casecontrol study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. Journal of Clinical Oncology 26:5530-5536.
14. Thompson D, Easton D. 2001. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. American Journal of Human Genetics 68:410-419.
15. Werness BA, Eltabbakh GH. 2001. Familial ovarian cancer and early ovarian cancer: biologic, pathologic, and clinical features. International Journal of Gynecological Pathology 20:48-63.
16. Werness BA, Ramus SJ, Whittemore AS, Garlinghouse-Jones K, Oakley-Girvan I, Dicioccio RA et al. 2000. Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Human Pathology 31:1420-1424.